Multiple Sclerosis and Natalizumab

@article{Fiore2007MultipleSA,
  title={Multiple Sclerosis and Natalizumab},
  author={Domenico Fiore},
  journal={American Journal of Therapeutics},
  year={2007},
  volume={14},
  pages={555-560}
}
  • D. Fiore
  • Published 1 November 2007
  • Medicine
  • American Journal of Therapeutics
Natalizumab (NTZ), defined as “the first of a new class of drugs known as elective adhesion molecule inhibitors” was developed at the beginning of 2003 to treat relapsing-remitting multiple sclerosis (MS) and was approved in the United States in November 2004. In February 2005, the production of NTZ was suspended by Producer Firms on account of the occurrence of two serious adverse events: two patients who had been taking NTZ manifested a progressive multifocal leukoencephalopathy; the patients… 

Monoclonal Antibodies as Therapeutic Agents

Immunoconjugates which are comprised of monoclonal antibody linked to a chemotherapeutic agent or source(s) of radiation are discussed to treat cancer.

Novel Anti-Inflammatory Action of Edelfosine Lacking Toxicity with Protective Effect in Experimental Colitis

The data identify edelfosine as a novel anti-inflammatory drug by abating neutrophil infiltration through L-selectin shedding and may provide a new therapeutic approach for inflammatory bowel disease free from toxicity.

Microsoft Word-40472801-file00

  • 2009

References

SHOWING 1-10 OF 22 REFERENCES

A controlled trial of natalizumab for relapsing multiple sclerosis.

In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.

Diagnosis and Treatment of Multiple Sclerosis and Amyotrophic Lateral Sclerosis: Neuropathies From Bordetella Pertussis

  • D. Fiore
  • Medicine, Biology
    American journal of therapeutics
  • 2003
The pathogenesis of the neuropathies from Bordetella pertussis is reassessed and an extended antibiotic therapy to clear mucosae and to prevent reinfections is necessary.

Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis

It is suggested that sICAM-1 index can be a better marker of intrathecal sICam-1 synthesis than CSF levels and provide additional insights, in vivo, into the blood-brain barrier mechanisms underlying MRI Gd-enhancement in clinically active RR MS.

MEDICO E BAMBINO PAGINE ELETTRONICHE

On the basis of the reviewed literature, in pediatric age the ideal bottled water should be rich in magnesium and calcium and have a low sodium content.

Le Vaccinazioni in Pediatria

  • Milano: Editrice C.S.H.,
  • 1993

Pertussis nell’Uomo – EOS

  • 2001

Immunologie. Paris: Flammarion, 1986:541

  • 1986

Immunopatogenesi della sclerosi multipla: ruolo della barriera emato-encefalica. From the Volume Abstract del Congresso SNO

  • 2000

Lipopolysaccharides et endotoxines

    Introduzione alla Immunologia Fondamentale. Milano: Mondadori; 1976:204

    • 1976